Evidence map›Paper›PMID 40474105›Full record

ArticleBMC cancer2025

Plasma cfDNA multi-omic biomarkers profiling for detection and stratification of gastric carcinoma.

Shiyi Song, Xiuli Zhang, Pin Cui, Weihuang He, Jiyuan Zhou, Shubing Wang, Yong Xiong, Shu Xu, Xiaohui Lin, Guozeng Huang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shiyi Song *Department of Endoscopy, The First Affiliated Hospital of Xinxiang Medical University, Weihui, 453100, China.
Xiuli Zhang *Department of Gastroenterology, Guangming District People's Hospital, Shenzhen, China.
Pin Cui *Shenzhen Rapha Biotechnology Incorporate, Shenzhen, China. cuipin@rafabio.com.
Weihuang He *Shenzhen Rapha Biotechnology Incorporate, Shenzhen, China.
Jiyuan Zhou *Department of Gastroenterology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shubing Wang *Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China.
Yong XiongDepartment of Gastrointestinal Surgery, Shenzhen Guangming District People's Hospital, Shenzhen, China.
Shu XuDepartment of Oncology, Shenzhen Guangming District People's Hospital, Shenzhen, China.
Xiaohui LinDepartment of Oncology, People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Guozeng HuangDepartment of Gastrointestinal Surgery, Shenzhen Guangming District People's Hospital, Shenzhen, China.
Xiaohua TanDepartment of Oncology, Shenzhen, Third People's Hospital, Shenzhen, China.
Qinglong XuDepartment of Gastroenterology, Guangming District People's Hospital, Shenzhen, China.
Yongling LiuDepartment of Gastroenterology, Guangming District People's Hospital, Shenzhen, China.
Qingqun LiDepartment of Gastroenterology, Guangming District People's Hospital, Shenzhen, China.
Kehua YuanDepartment of Oncology, Yantian Hospital, South University of Science and Technology, Shenzhen, Guangdong, China.
Mingji FengShenzhen Rapha Biotechnology Incorporate, Shenzhen, China.
Hanming LaiShenzhen Rapha Biotechnology Incorporate, Shenzhen, China.
Hui YangDepartment of Gastroenterology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shaorong ZhangDepartment of Gastroenterology, Guangming District People's Hospital, Shenzhen, China. zsr3380320@sina.com.

Funding

Shenzhen Rapha Biotechnology Incorporate R&D Clinical Study Fund RFCS20210701001Shenzhen San-Ming Project of Medicine SZSM2022-11036Shenzhen Science and Technology Innovation Commission Project KCXFZ20200201101050887
6 · The paper itself

Abstract

Despite being the third in death rate among all cancers globally, gastric carcinoma (GC) is far from being detected accurately and timely, which could benefit the prognosis. To achieve this, we performed whole-genome sequencing (WGS) to plasma cfDNA of 733 participants, including healthy individuals, patients with benign gastric diseases and GC patients. The multi-omic biomarkers in this study, including fragmentation profile, end motif and genome-wide Copy Number Variations (CNV) of plasma cfDNA, are recently developed means for cancer detection and monitoring. And these biomarkers were extracted from WGS data to build machine learning algorithm based classifiers, prediction models, to discriminate GC patients from healthy individuals, achieving extremely high precision of sensitivity at 94.87% and specificity at 99.35%. Therefore, these cfDNA multi-omic biomarkers may serve as means to detect GC accurately, affordably and timely.

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsStomach NeoplasmsAdultAgedCase-Control StudiesDNA Copy Number VariationsFemaleHumansMachine LearningMaleMiddle AgedMultiomicsPrognosisWhole Genome SequencingBiomarkers, TumorCell-Free Nucleic AcidsCell-free DNA(cfDNA)Epigenetic modificationGastric carcinoma(GC)Machine learningTranscription factor binding site(TFBS)Whole genome sequencing (WGS)

Identifiers

PMID40474105
PMCPMC12139387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.